Christopher Raymond
Stock Analyst at Piper Sandler
(2.68)
# 1,927
Out of 5,142 analysts
140
Total ratings
52.17%
Success rate
1.9%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Overweight | $39 → $52 | $37.06 | +40.31% | 2 | Feb 18, 2026 | |
| ARDX Ardelyx | Upgrades: Overweight | $10 → $16 | $5.75 | +178.26% | 11 | Jan 9, 2026 | |
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $6.35 | +293.70% | 1 | Dec 18, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $4.84 | +168.60% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $7.54 | +284.62% | 2 | Oct 21, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $132.91 | -47.33% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $196.34 | -41.43% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $2.42 | +271.90% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $62.92 | +100.25% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $4.58 | -12.66% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $227 | $229.48 | -1.08% | 12 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $481.01 | +10.81% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $787.04 | +28.71% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $22.51 | +521.95% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $55.80 | +29.03% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $3.25 | +300.00% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $10.03 | +647.76% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $11.58 | +556.30% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.34 | +2,859.46% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $33.30 | -0.90% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.21 | +230.58% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $379.42 | -24.09% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $30.20 | +35.76% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $47.44 | -40.98% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $103.00 | -61.17% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.87 | +1,433.22% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.81 | +5,203.87% | 2 | Mar 13, 2020 |
Cogent Biosciences
Feb 18, 2026
Maintains: Overweight
Price Target: $39 → $52
Current: $37.06
Upside: +40.31%
Ardelyx
Jan 9, 2026
Upgrades: Overweight
Price Target: $10 → $16
Current: $5.75
Upside: +178.26%
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $6.35
Upside: +293.70%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $4.84
Upside: +168.60%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $7.54
Upside: +284.62%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $132.91
Upside: -47.33%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $196.34
Upside: -41.43%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $2.42
Upside: +271.90%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $62.92
Upside: +100.25%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $4.58
Upside: -12.66%
Jan 27, 2025
Maintains: Overweight
Price Target: $220 → $227
Current: $229.48
Upside: -1.08%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $481.01
Upside: +10.81%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $787.04
Upside: +28.71%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $22.51
Upside: +521.95%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $55.80
Upside: +29.03%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $3.25
Upside: +300.00%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $10.03
Upside: +647.76%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $11.58
Upside: +556.30%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.34
Upside: +2,859.46%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $33.30
Upside: -0.90%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.21
Upside: +230.58%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $379.42
Upside: -24.09%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $30.20
Upside: +35.76%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $47.44
Upside: -40.98%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $103.00
Upside: -61.17%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.87
Upside: +1,433.22%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.81
Upside: +5,203.87%